Rtw Investments LP, 10% Owner, bought 1,200,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $6M in total on Nov 9, 2026. Shares held after the trade: 10,756,063 (+12.6%).
Orchestra BioMed reported a significant decrease in total revenue to $0.29 million for the nine months ended September 30, 2026, compared to $2.57 million in the prior year, primarily due to the absence of partnership revenue. The company's total stockholders' equity declined from $53.6 million to $7.8 million as the accumulated deficit reached $425.8 million.
Orchestra BioMed Holdings Insider Eric S. Fain Buys $100K of Stock
Eric S. Fain bought 20,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $100K in total on Nov 9, 2026. Shares held after the trade: 119,630 (+20.1%).
Orchestra BioMed Holdings Insider David Pacitti Buys $100K of Stock
David Pacitti bought 20,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $100K in total on Nov 9, 2026. Shares held after the trade: 74,750 (+36.5%).
Orchestra BioMed Holdings Insider David P. Hochman Buys $25K of Stock
David P. Hochman bought 5,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $25K in total on Nov 9, 2026. Shares held after the trade: 437,916 (+1.2%).
Orchestra BioMed closed an underwritten public offering of 17,250,000 shares of common stock, which included the full exercise of the underwriters' over-allotment option. The offering was priced at $5.00 per share, generating gross proceeds of approximately $86.3 million. The company intends to use the funds to support its AVIM Therapy and Virtue SAB clinical programs, including the BACKBEAT global pivotal trial.
Orchestra BioMed Holdings Insider Darren Sherman Sells $86.1K of Stock
Darren Sherman sold 15,000 shares of Orchestra BioMed Holdings, Inc. at $5.74 a share, worth $86.1K in total on Nov 2, 2026. Shares held after the trade: 1,104,402 (-1.3%).
Orchestra BioMed Holdings Insider Darren Sherman Sells $95.4K of Stock
Darren Sherman sold 15,000 shares of Orchestra BioMed Holdings, Inc. at $6.36 a share, worth $95.4K in total on Oct 1, 2026. Shares held after the trade: 1,119,402 (-1.3%).
Orchestra BioMed exceeded its enrollment target for the BACKBEAT Global Pivotal Trial, randomizing 330 patients across 81 sites globally. The trial is evaluating AVIM Therapy for uncontrolled hypertension in pacemaker patients in collaboration with Medtronic. The company expects to submit primary endpoint data for presentation at a major cardiovascular conference in Q2 2027.